Exor Capital LLP Recursion Pharmaceuticals, Inc. Transaction History
Exor Capital LLP
- $2.78 Billion
- Q2 2024
A detailed history of Exor Capital LLP transactions in Recursion Pharmaceuticals, Inc. stock. As of the latest transaction made, Exor Capital LLP holds 3,675,077 shares of RXRX stock, worth $23.5 Million. This represents 0.99% of its overall portfolio holdings.
Number of Shares
3,675,077
Previous 2,175,077
68.96%
Holding current value
$23.5 Million
Previous $21.7 Million
27.11%
% of portfolio
0.99%
Previous 0.97%
Shares
4 transactions
Others Institutions Holding RXRX
# of Institutions
291Shares Held
241MCall Options Held
984KPut Options Held
2.4M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl32.8MShares$210 Million2.05% of portfolio
-
Baillie Gifford & CO26.6MShares$170 Million0.16% of portfolio
-
Vanguard Group Inc Valley Forge, PA21.6MShares$138 Million0.0% of portfolio
-
Black Rock Inc. New York, NY17.3MShares$111 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA15.4MShares$98.5 Million1.74% of portfolio
About RECURSION PHARMACEUTICALS, INC.
- Ticker RXRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 180,480,000
- Market Cap $1.16B
- Description
- Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cav...